Results 71 to 80 of about 1,446 (206)

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Effects of Dopamine Administration on Anxiety in Male Rat

مجله دانشکده پزشکی اصفهان, 2007
Background: Abstract Anxiety is a common disease in the society. Several neurotransmitters. The aim of this study was to investigate indirect effect of dopamine on anxiety in rat.
Hojatallah Alaei, Ruhollah Mouloudi, Mohammad Reza Sharifi, Mahmoud Hosseini, Abdollah Ahmadi   +4 more
doaj  

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Cell Death and Disease
Small cell lung cancer (SCLC) is difficult to treat due to its aggressiveness, early metastasis, and rapid development of resistance to chemotherapeutic agents.
Sk. Kayum Alam, Anuradha Pandit, Li Wang, Seyedeh Sahar Mortazavi Farsani, Britteny A. Thiele, Parvathy Manoj, Marie Christine Aubry, Vivek Verma, Charles M. Rudin, Ying-Chun Lo, Luke H. Hoeppner   +10 more
doaj   +1 more source

Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Cognitive fluctuations (CFs) are a disabling feature in Parkinson's disease dementia (PDD) and contribute to caregiver burden. The relationship between CFs and neurogenic orthostatic hypotension (nOH), a common autonomic complication in PDD, has not been adequately examined.
Jorge Patino, Kevin Duque, Jesus Abanto, Aaron Bloemer, Heba Deraz, Alberto J. Espay, Abhimanyu Mahajan   +6 more
wiley   +1 more source

Reinforcing properties of Pramipexole in normal and parkinsonian rats

Neurobiology of Disease, 2013
Striatal D2 and D3 dopamine receptors are involved in mediating the reinforcing properties of natural rewards and drugs. In Parkinson's disease, while D2/3 dopamine agonists alleviate motor symptoms, behavioral addictions and withdrawal syndrome are ...
Michel Engeln, Serge H. Ahmed, Caroline Vouillac, François Tison, Erwan Bezard, Pierre-Olivier Fernagut   +5 more
doaj   +1 more source

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study (PREMANDYSK)

Movement Disorders, EarlyView.
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol, Fabienne Ory‐Magne, Wassilios G. Meissner, David Maltête, Luc Defebvre, Jean‐Philippe Azulay, Stéphane Thobois, Jean‐Luc Houeto, Claire Thalamas, Agnès Sommet, Christian Geny, Philippe Damier, Mathieu Anheim, Ana Marquès, François Viallet, Maurice Giroud, Romain Lefaucheur, Guillaume Costentin, Umberto Spampinato, Alexandra Samier‐Foubert, Nicolas Carrière, Eugénie Mutez, Louise‐Laure Mariani, Alexandre Eusebio, Stéphane Prange, Isabelle Benatru, Mahmoud Charif, Christine Brefel‐Courbon, Margherita Fabbri, Monique Galitzky, Vanessa Rousseau, Amandine Saubion, Hélène Catala, Joaquim J. Ferreira, David J. Burn, Jean‐Christophe Corvol, on behalf of the PREMANDYSK Study Group, Olivier Rascol, Fabienne Ory‐Magne, Claire Thalamas, Jean‐Christophe Corvol, Luc Defebvre, Wassilios G Meissner, David Maltête, Jean‐Philippe Azulay, Jean‐Luc Houeto, Stéphane Thobois, François Viallet, Alexandra Samier‐Foubert, Umberto Spampinato, Thomas Boraud, François Tison, Franck Durif, Ana Marques, Bérengère Debilly, Stéphane Bernard, Maurice Giroud, Nicolas Carrière, Eugénie Mutez, Frederic Torny, Philippe Couratier, Oliver Colin, Thomas Gaudin, Pierre Boutet, Emmanuel Broussolle, Stéphane Prange, Cathrine Caire, Hélène Merle, Alexandre Eusebio, Manel Nouira, Christian Geny, Mahmoud Charif, Philippe Damier, Pascal Derkinderen, Mirela Faighel, Violaine Talmant, Severine LeDily, Louise‐Laure Mariani, Lucette Lacomblez, Anne‐Marie Bonnet, Isabelle Benatru, Jean‐Luc Houeto, Solène Ansquer, Emilie Rabois, Anne Fradet, Romain Lefaucheur, Guillaume Costentin, Linda Vernon, Christine Tranchant, Matthieu Anheim, Ouhaid Lagha‐Boukbiza, Thomas Wirth, Agnès Sommet, Vanessa Rousseau, Hélène Catala, Monique Galiztky, Amandine Saubion, Christine Brefel‐Courbon, Margherita Fabbri, Nadéra Ainaoui, Estelle Dellapina, Alexandra Salis, Frédéric Eyvrard, Camille Jurado, Nicolas Boulloche, Jany Rey‐Zermati, Jean Jaques Boulesteix   +106 more
wiley   +1 more source

Therapeutic challenges of giant invasive cystic macroprolactinoma

Endocrinology, Diabetes & Metabolism Case Reports
Giant cystic prolactinomas are extremely rare, with only four cases previously reported in the literature. Herein, we report the case of a 59-year-old male who presented with an acute decline in visual acuity.
S Mekni, H Khiari, S Bouali, R Laamouri, S Essayeh, I Rojbi, I Ben Nacef   +6 more
doaj   +1 more source

Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is associated with several behavioral and cognitive symptoms, the neurobiological background of which is not yet fully understood. Objectives The aim was to investigate the association between monoamine function and four specific nonmotor symptoms in early PD using the Parkinson's Progression Markers ...
Kalle J. Niemi, Valtteri Kaasinen, Rimona S. Weil, Juho Joutsa   +3 more
wiley   +1 more source

Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease is mainly characterized by dopaminergic neurodegeneration in the substantia nigra pars compacta (SNc) and α‐synuclein accumulation. The locus coeruleus (LC) is also affected in Parkinson's disease and linked to some nonmotor symptoms, but the extent and timing of its degeneration remain unclear.
Megan Carrillo, Nagore Hernández‐Pinedo, Josefa Zaldivar‐Diez, Isabel Pérez‐Santos, José A. Obeso, Carmen Cavada, Javier Blesa   +6 more
wiley   +1 more source